Xunwei Jun Named 'Leading Enterprise' and '2024 Most Influential Company' in Greater Bay Area Biotech Innovation Top 50

On December 26, the award ceremony for the 7th Greater Bay Area Biotechnology Innovation Top 50 was held in Guangzhou. The event was hosted by the Zhongchuang Industry Research Institute and organized by Guangdong Medical Valley. Numerous top experts, investors, entrepreneurs, and media from the biotechnology industry gathered in Guangzhou to witness the birth of this year's Top 50 enterprises.

Xbiome Honored with Two Major Awards: "Leading Enterprise" and "2024 Influential Enterprise" in the Top 50 Biotech Innovations of the Guangdong-Hong Kong-Macao Greater Bay Area, and Invited to Deliver a Speech as a Representative of Leading Enterprises.

According to the "7th Greater Bay Area Top 50 Biotech Companies Innovation Report," the Greater Bay Area is gradually forming a vibrant and highly competitive life sciences industrial cluster. The top 50 companies have achieved remarkable results in market application, innovation capability, capital elements, and industry influence, among other aspects. Among them, there are 17 listed companies, and over 40% of the companies have reached Series B funding or beyond. In the 7th edition of the top 50 companies, 49% are high-tech enterprises, and 29% are provincial or municipal specialized and sophisticated enterprises. The average establishment time of leading companies is 11.9 years, with an average of 191 employees.

Among the 10 leading companies, Xbiome, focusing on human gut microbiome research and product development, has achieved remarkable success in scientific research, drug development, and commercialization with faster growth and a highly efficient core team. In the past year, Xbiome’s scientific research achievements have been continuously published in globally renowned academic journals; its drug clinical trials have progressed smoothly under the regulatory systems of both China and the U.S.; in the large health sector such as fecal microbiota transplantation and probiotics, it has also swiftly completed product and solution development, achieving significant commercial success. Ultimately, Xbiome stood out among the flourishing biotech companies in the Greater Bay Area, earning the titles of "Leading Enterprise" and "2024 Influential Enterprise of the Year."

Shu Yuan, Dean of Zhongchuang Industry Research Institute, stated in his speech that the Top 50 Organizing Committee conducted on-site investigations to gain an in-depth understanding of enterprises, comprehensively evaluating the performance of participating companies in core product development, service quality improvement, R&D team building, technology patent acquisition, and corporate financial management. Yan Zhen, Member of the Party Leadership Group and Deputy Director of the Guangdong Provincial Drug Administration, highly praised the Top 50 event for providing a professional exchange platform for numerous biotech companies, helping them expand industrial resources during their development process, accelerate growth, and promote high-quality development of the biopharmaceutical industry.

Xbiome stated in its address that it will continue to deepen its expertise in fecal microbiota transplantation technology, providing hospitals and health institutions with more precise and higher-quality treatment technologies and solutions. It will continuously deliver innovative functional strains, empowering industry partners such as probiotics, food, and dairy companies through its research capabilities. Additionally, Xbiome will further advance drug research and clinical trials, striving to become a representative of new productive forces in the Greater Bay Area, contributing its strength to the development of China's biopharmaceutical industry, both in the Greater Bay Area and beyond.

-End-